DKTK Core Facility: PDX Models

Xenograft Mouse Models of Acute Leukemia 
 

Following services are offered in the DKTK Core Facility PDX Models:

  • Xenotransplantation and amplification of primary leukemia cells of ALL or AML patients in NSG mice
  • Generation of serially transplantable and robust patient-derived xenograft (*PDX) cells
  • Genetic engineering of PDX cells for transgenic expression of, e.g., luciferase or Cas9
Generation of *PDX models of ALL and AML and genetic engineering. © AG Jeremias

 

Functional, molecular and therapy in vivo and ex vivo trials conducted with *PDX models. © AG Jeremias

 

  • Preclinical in vivo therapy trials, monitored by bioluminescence in vivo imaging for continous, real-time assessment of therapy response
    • Monitoring of clinically-relevant response rates and disease stages, e.g. minimal residual disease
    • Analysis of subpopulations, e.g. dormant cells
    • Analysis of molecular derivatives, e.g. with knockout of a gene-of-interest
Bioluminescence in vivo imaging allows reliable and sensitive follow-up of preclinical treatment trials. © AG Jeremias

 

More information about the Xenocraft Core Facility Munich

Coordination

#
Prof. Dr. Irmela Jeremias

Dr. von Haunersches Kinderspital der LMU München & Helmholtz Munich

Feodor-Lynen-Str. 21
81377 München
Send message
#
Dr. Binje Vick

Helmholtz Munich

Feodor-Lynen-Str. 21
81377 München
Send message